You have read all your free articles, to continue reading subscribe to read the rest of this content.
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. The Phase III trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 or COVID-19-related deaths in Already a subscriber Login You…
Iconovo has signed an agreement with Immune System Regulation (ISR) for the development of an inhaled COVID-19 vaccine in Iconovo’s inhaler ICOone. The agreement is Iconovo’s second agreement within its newest strategic area innovative inhalation projects. The agreement gives ISR exclusive riAlready a subscriber Login You have read all your…
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, nonAlready a subscriber Login You have…
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorization (CMA) in the European Union (EU) for active immunization to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Following review of the application, the Committee for Medicinal ProAlready a subscriber Login You have read all…
